Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prestige Consumer Healthcare (PBH) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Prestige Consumer Healthcare (PBH) over the last 17 years, with Q4 2025 value amounting to $62.4 million.

  • Prestige Consumer Healthcare's Cash & Equivalents rose 2260.29% to $62.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $62.4 million, marking a year-over-year increase of 2260.29%. This contributed to the annual value of $97.9 million for FY2025, which is 11064.37% up from last year.
  • According to the latest figures from Q4 2025, Prestige Consumer Healthcare's Cash & Equivalents is $62.4 million, which was up 2260.29% from $119.1 million recorded in Q3 2025.
  • Over the past 5 years, Prestige Consumer Healthcare's Cash & Equivalents peaked at $163.6 million during Q2 2021, and registered a low of $21.0 million during Q4 2021.
  • For the 5-year period, Prestige Consumer Healthcare's Cash & Equivalents averaged around $64.5 million, with its median value being $53.1 million (2023).
  • Within the past 5 years, the most significant YoY rise in Prestige Consumer Healthcare's Cash & Equivalents was 31087.64% (2022), while the steepest drop was 7807.84% (2022).
  • Prestige Consumer Healthcare's Cash & Equivalents (Quarter) stood at $21.0 million in 2021, then surged by 310.88% to $86.4 million in 2022, then dropped by 26.34% to $63.6 million in 2023, then dropped by 20.03% to $50.9 million in 2024, then rose by 22.6% to $62.4 million in 2025.
  • Its Cash & Equivalents stands at $62.4 million for Q4 2025, versus $119.1 million for Q3 2025 and $139.5 million for Q2 2025.